CP 154526

Drug Profile

CP 154526

Alternative Names: antalarmin

Latest Information Update: 20 Jun 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Eisai Co Ltd; Pfizer
  • Class Antidepressants
  • Mechanism of Action Corticotropin-releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anxiety disorders; Major depressive disorder

Most Recent Events

  • 08 Dec 2000 Preclinical development for Anxiety disorders in Japan (Unknown route)
  • 08 Dec 2000 A study has been added to the Anxiety Disorders pharmacodynamics section
  • 03 May 2000 No-Development-Reported for Anxiety disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top